East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Naproxen Oral Suspension USP, 125 mg/5 mL. Aurobindo Pharma’s Naproxen Oral Suspension, are an AB-rated generic equivalent to the reference listed drug (RLD), Naprosyn Oral Suspension manufactured by Atnahs Pharma US Limited.

Naproxen Oral Suspension are indicated for:

• the relief of the signs and symptoms of:
  • rheumatoid arthritis
  • osteoarthritis
  • ankylosing spondylitis
  • polyarticular juvenile idiopathic
  • arthritis
  • tendonitis
  • bursitis
  • acute gout
• the management of:
  • pain
  • primary dysmenorrhea .